Federal Register / Vol. 65, No. 203 / Thursday, October 19, 2000 / Notices 62737

Data collection instrument

Estimated

number of respondents

Responses

per respondent

Annual number of responses

Average burden hour

per response*

Total annual

burden hours

Table 8 .................................................................. 34 1 34 0.94 (56 min) ................ 32.0

Total ............................................................... 261 1 261 313.0

For ease of understanding, burden hours are also provided in actual minutes.

**Excludes urban Indian health projects with no medical component.

There are no Capital Costs, Operating

Costs and/or Maintenance Costs

required for this collection of

information.

REQUEST FOR COMMENTS: Your written

comments and/or suggestions are

invited on one or more of the following

points: (a) Whether the information

collection activity is necessary to carry

out an agency function; (b) whether the

IHS processes the information collected

in a useful and timely fashion; (c) the

accuracy of the public burden estimate

(the estimated amount of time needed

for individual respondents to provide

the requested information); (d) whether

the methodology and assumptions used

to determine the estimates are logical;

(e) ways to enhance the quality, utility,

and clarity of the information being

collected; and (f) ways to minimize the

public burden through the use of

automated, electronic, mechanical, or

other technological collection

techniques or other forms of information

technology.

Direct Comments to OMB: Send your

written comments and suggestions

regarding the proposed information

collection contained in this notice,

especially regarding the estimated

public burden and associated response

time, to: Office of Management and

Budget, Office of Regulatory Affairs,

New Executive Office Building, Room

10235, Washington, DC 20503,

Attention: Desk Officer for IHS.

To request more information on the

proposed collection or to obtain a copy

of the data collection instrument(s) and/

or instructions(s), contact: Mr. Lance

Hodahkwen, Sr., M.P.H., IHS Reports

Clearance Officer, 12300 Twinbrook

Parkway, Suite 450, Rockville, MD

20852.1601, or call non-toll free (301)

443–5938 or send via facsimile to (301)

443–2316, or send your E-mail requests,

comments, and return address to:

lhodahkw@hqe.ihs.gov.

Comments Due Date: Comments

regarding this information collection are

best assured of having their full effect if

received on or before November 20,

2000.

Dated: October 13, 2000.

Michael H. Trujillo,

Assistance Surgeon General Director.

[FR Doc. 00–26896 Filed 10–18–00; 8:45 am]

BILLING CODE 4160–16–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of

Closed Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. appendix 2), notice

is hereby given of the following

meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Cancer

Institute Special Emphasis Panel, SPORES.

Date: October 25–27, 2000.

Time: 8 AM to 6 PM.

Agenda: To review and evaluate grant

applications.

Place: Holiday Inn—Georgetown, 2101

Wisconsin Avenue, NW, Washington, DC

20007.

Contact Person: Brian E. Wojcik, PhD,

Scientific Review Administrator, Grants

Review Branch, Division of Extramural

Activities, National Cancer Institute, 6116

Executive Boulevard, Room 8019, Bethesda,

MD 20892, 301/402–2785.

This notice is being published less than 15

days prior to the meeting due to the timing

limitations imposed by the review and

funding cycle.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.392, Cancer Construction;

93.393, Cancer Cause and Prevention

Research; 93.394, Cancer Detection and

Diagnosis Research; 93.395, Cancer

Treatment Research; 93.396, Cancer Biology

Research; 93.397, Cancer Centers Support;

93.398, Cancer Research Manpower; 93.399,

Cancer Control, National Institutes of Health,

HHS)

Dated: October 12, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 00–26854 Filed 10–18–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of

Closed Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Cancer

Institute Special Emphasis Panel; Improving

DNA, RNA, and Protein Availability in Fixed

Tissue.

Date: November 15, 2000.

Time: 8 a.m. to 3 p.m.

Agenda: To review and evaluate grant

applications.

Place: Ramada Inn Rockville, 1775

Rockville Pike, Rockville, MD 20852.

Contact Person: Gerald G. Lovinger, PhD,

Scientific Review Administrator, Grants

Review Branch, Division of Extramural

Activities, National Cancer Institute, National

Institutes of Health, 6116 Executive

Boulevard, Room 8070, Rockville, MD

20892–7405, 301/496–7987.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.392, Cancer Construction;

93.393, Cancer Cause and Prevention

Research; 93.394, Cancer Detection and

Diagnosis Research; 93.395, Cancer

Treatment Research; 93.396, Cancer Biology

Research; 93.397, Cancer Centers Support;